Rajiv Rampat, MD

Original Contribution

Predicting the Need For Permanent Pacing After Implantation of the Repositionable Lotus Transcatheter Aortic Valve

09/01/2020

James Cockburn , MBBS, MD, FRCP;

Rajiv Rampat , MD;

Adam de Belder , MD, FRCP;

Roly Hilling-Smith , MD;

Maureen Dooley , MRCP, MD;

Tiffany Kemp , MD;

Andrew Hill , MD;

Uday Trivedi , MD;

Michele Homsy , MD;

David Hildick-Smith , MD, MBBS, FRCP;

Permanent pacemaker implantation rates vary according to type of transcatheter aortic valve implantation (TAVI) device, implantation technique, and patient-related factors. We analyzed the baseline characteristics, and then the preprocedure...

Permanent pacemaker implantation...

09/01/2020

Journal of Invasive Cardiology

Original Contribution

Clinical Outcomes in Patients Treated With Biodegradable-Polymer Biolimus-Eluting Stents and 6 Months of Dual-Antiplatelet Therapy: The French eBiomatrix 6-Month DAPT Registry

05/01/2022

Antoine Gommeaux , MD;

Vincent Malquarti , MD;

Denis Angoulvant , MD;

Clauset Cruchon , MD;

Keith G. Oldroyd , MD, MBChB, FRCP;

Christian Spaulding , MD;

Hakim Benamer , MD;

Thierry Lefèvre , MD;

Olivier Varenne , MD;

Janusz Lipiecki , MD;

Rajiv Rampat , MD;

Christophe Piot , MD;

François Brunelle , MD;

Rami el Mahmoud , MD;

Dual-antiplatelet treatment (DAPT) has conventionally been prescribed for 1 year after percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation. Recent evidence suggests that a duration of only 6 months may be...

Dual-antiplatelet treatment...

05/01/2022

Journal of Invasive Cardiology